Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?

D. A. Messner, P. Rabins, A. C. Downing, M. Irizarry, N. L. Foster, J. Al Naber, O. Dabbous, H. Fillit, S. Gabler, R. Krakauer, D. Lotz, E. Payzant, L. Schneider, J. Tyrone, D. Van Amerongen, D. Wuest

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?'. Together they form a unique fingerprint.

Medicine & Life Sciences